The DOI matches its Crossref record; 157 of the 159 references it cites were found in a registry or an index.
TIM3 comes of age as an inhibitory receptor
Open accessAbstract
T cell immunoglobulin and mucin domain-containing protein 3 (TIM3), a member of the TIM family, was originally identified as a receptor expressed on interferon-γ-producing CD4+ and CD8+ T cells. Initial data indicated that TIM3 functioned as a 'co-inhibitory' or 'checkpoint' receptor, but due to the lack of a definable inhibitory signalling motif, it was also suggested that TIM3 might act as a co-stimulatory receptor. Recent studies have shown that TIM3 is part of a module that contains multiple co-inhibitory receptors (checkpoint receptors), which are co-expressed and co-regulated on dysfunctional or 'exhausted' T cells in chronic viral infections and cancer. Furthermore, co-blockade of TIM3 and programmed cell death 1 (PD1) can result in tumour regression in preclinical models and can improve anticancer T cell responses in patients with advanced cancers. Here, we highlight the developments in understanding TIM3 biology, including novel ligand identification and the discovery of loss-of-function mutations associated with human disease. In addition, we summarize emerging data from human clinical trials showing that TIM3 indeed acts as a 'checkpoint' receptor and that inhibition of TIM3 enhances the antitumour effect of PD1 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, tyrosine kinase FYN and human leukocyte antigen B (HLA‐B)‐associated transcript 3 (BAT3) were suggested to inhibit the cytoplasmic tail of TIM‐3 signaling [307, 308, 309].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [307]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the latter of which encodes the checkpoint molecule TIM3, one of the most promising new therapeutic approaches in cancer 32 that was recently described in a GWAS as an AD risk gene 2 .”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Self-citationMiller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Self-citationDefining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Self-citationDefining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Research works printed but not linked: 2
- Weiss, G. J. et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors. J. Immunother. Cancer 5, 86 (2017).
- Davar, D. et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma. J. Immunother. Cancer 6, 115 (2018).
Cited by
Sorted by citations
Items 201–300 of 963
Jiang, Y., Wang, Z., Zhong, M., Shen, L., Han, X., Zou, X., Liu, X.-Y., Deng, Y.-N., Yang, Y., Chen, G., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1908010 · Cited by 37
Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma
Jain, S., Chalif, E. J., & Aghi, M. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.812916 · Cited by 36
Bailly, C., Thuru, X., Goossens, L., & Goossens, J. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115445 · Cited by 35
Targeting tumor metabolism to augment CD8+ T cell anti-tumor immunity
Liu, H., Yang, W., & Jiang, J. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101150 · Cited by 38
Yang, Z., Shan, N., Deng, Q., Wang, Y., Hou, Y., Mei, J., & Wu, Z. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16234 · Cited by 35
TIM‐3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways
Kikushige, Y. (2021) · Cancer Science · doi:10.1111/cas.15042 · Cited by 36
Wong, W., Yin, B., Lam, C. Y. K., Huang, Y., Yan, J., Tan, Z., & Wong, S. H. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.783227 · Cited by 35
Hudry, D., Guellec, S. L., Meignan, S., Bécourt, S., Pasquesoone, C., Hajj, H. E., Martínez-Gómez, C., Leblanc, É., Narducci, F., & Ladoire, S. (2022) · Cancers · doi:10.3390/cancers14215332 · Cited by 35
Láníčková, T., Hensler, M., Kašíková, L., Vosahlikova, S., Angelidou, A., Pasulka, J., Griebler, H., Drozenová, J., Mojžíšová, K., Vankerckhoven, A., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1594 · Cited by 34
Martinez, M. C., Kim, S., Jean, N. S., O’Brien, S., Lian, L., Sun, J., Verona, R. I., & Moon, E. K. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1873607 · Cited by 35
Liao, C., Wang, Y., Huang, Y., Duan, Y., Liang, Y., Chen, J., Jiang, J., Shang, K., Zhou, C., Gu, Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202207394 · Cited by 33
Abdel‐Rahman, S. A., Talagayev, V., Pach, S., Wolber, G., & Gabr, M. T. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00960 · Cited by 33
Chen, H., Moussa, M., & Catálfamo, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01223 · Cited by 33
Comprehensive analysis of radiosensitivity in head and neck squamous cell carcinoma
Li, G., Jiang, Y., Li, G., & Qiao, Q. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.03.017 · Cited by 35
Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets
Zhou, X., Ren, T., Zan, H., Hua, C., & Guo, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864202 · Cited by 33
Induction of pyroptotic cell death as a potential tool for cancer treatment
Faria, S. S., Fernando, A. J., de Lima, V. C. C., Rossi, A. G., de Carvalho, J. M. A., & Magalhães, K. G. (2022) · Journal of Inflammation · doi:10.1186/s12950-022-00316-9 · Cited by 33
Ciraolo, E., Althoff, S., Ruß, J., Rosnev, S., Butze, M., Pühl, M., Frentsch, M., Bullinger, L., & Na, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063207 · Cited by 36
Song, J. Y., Nwangwu, M., He, T.-F., Zhang, W., Meawad, H., Bedell, V., Murata‐Collins, J. L., Skrabek, P., Nasr, M. R., Scott, D., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282265 · Cited by 34
Tim-3 Expression Causes NK Cell Dysfunction in Type 2 Diabetes Patients
Wang, H., Cao, K., Liu, S., Xu, Y., & Tang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.852436 · Cited by 32
Gallazzi, M., Ucciero, M. A. M., Faraci, D., Mahmoud, A. M., Essa, W. A., Gaïdano, G., Mouhssine, S., & Crisà, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147542 · Cited by 32
Xie, Q., Zhang, P., Wang, Y., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.958720 · Cited by 35
Abdeladhim, M., Karnell, J. L., & Rieder, S. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1033705 · Cited by 32
Greco, L., Rubbino, F., Buono, A. D., & Laghi, L. (2023) · Genes · doi:10.3390/genes14061169 · Cited by 35
Salminen, A. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102694 · Cited by 33
Signaling Dynamics Regulating Crosstalks between T-Cell Activation and Immune Checkpoints
Kreileder, M., Barrett, I. P., Bendtsen, C., Brennan, D. J., & Kölch, W. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.12.001 · Cited by 31
TIM3+ cells in gastric cancer: clinical correlates and association with immune context
Chen, K., Gu, Y., Cao, Y., Fang, H., Lv, K., Liu, X., He, X., Wang, J., Lin, C., Liu, H., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01607-3 · Cited by 30
Immune checkpoint molecule Tim-3 promotes NKT cell apoptosis and predicts poorer prognosis in Sepsis
Wu, H., Tang, T.-X., Deng, H., Chen, D., Zhang, C., Luo, J., Chen, S., Zhang, P., Yang, J., Dong, L., et al. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109249 · Cited by 31
Zhang, Y., Song, Y., Wang, X., Shi, M., Lin, Y., Tao, D., & Han, S. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0418 · Cited by 30
Influence of Microbiota on Tumor Immunotherapy
Yu, X., Li, W., Li, Z., Wu, Q., & Sun, S. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91771 · Cited by 33
Franzese, O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312848 · Cited by 29
Mucosal Associated Invariant T Cells in Cancer-Friend or Foe?
O’Neill, C. A., Cassidy, F. C., O'Shea, D. B., & Hogan, A. E. (2021) · Cancers · doi:10.3390/cancers13071582 · Cited by 29
Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies
Belli, C., Antonarelli, G., Repetto, M., Bielo, L. B., Crimini, E., & Curigliano, G. (2022) · Cancers · doi:10.3390/cancers14174278 · Cited by 31
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors
Whalen, K. A., Rakhra, K., Mehta, N. K., Steinle, A., Michaelson, J. S., & Baeuerle, P. A. (2023) · mAbs · doi:10.1080/19420862.2023.2208697 · Cited by 33
Katagata, M., Okayama, H., Nakajima, S., Saito, K., Sato, T., Sakuma, M., Fukai, S., Endo, E., Sakamoto, W., Saito, M., et al. (2023) · Cancers · doi:10.3390/cancers15204943 · Cited by 31
Zhu, Q., Yang, Y., Chen, K., Zhang, Q., Huang, Y., & Jian, S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05002-3 · Cited by 30
Cid, L. L., Wong, J., Botana, I. F., Paul, Y., Wierz, M., Pilger, L.-M., Floerchinger, A., Tan, C. L., Gonder, S., Pagano, G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61822-x · Cited by 33
Using CRISPR to enhance T cell effector function for therapeutic applications
Heeren, J. J. F. (2020) · Cytokine X · doi:10.1016/j.cytox.2020.100049 · Cited by 31
Wang, F., Yang, M., Luo, W., & Zhou, Q. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.002 · Cited by 33
Phytochemicals in regulating PD ‐1/ PD‐L1 and immune checkpoint blockade therapy
Zhong, C., Yang, C., Gao, X., Dong, J., & Zhong, C. (2023) · Phytotherapy Research · doi:10.1002/ptr.8082 · Cited by 30
Ran, X., Zheng, J., Chen, L., Xia, Z., Wang, Y., Sun, C., Guo, C., Lin, P., Liu, F., Wang, C., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0211 · Cited by 30
Roussot, N., Kaderbhaï, C., & Ghiringhelli, F. (2025) · Cancers · doi:10.3390/cancers17050906 · Cited by 29
Immune checkpoints regulate acute myeloid leukemia stem cells
Reinhardt, C., & Ochsenbein, A. F. (2025) · Leukemia · doi:10.1038/s41375-025-02566-x · Cited by 28
Miao, H., Yuan, F., Pan, C.-X., Yang, H., Wang, Z., Qi, Y., Wu, Y. Z., Zhang, Y., Liu, F., Huang, H., et al. (2025) · Medicine Plus · doi:10.1016/j.medp.2025.100087 · Cited by 33
Picón, C., Velarde, A. T., Fernández-Velasco, J. I., Comabella, M., Álvarez‐Lafuente, R., Quintana, E., de la Maza, S. S., Monreal, E., Villarrubia, N., Alvarez-Cermeño, J. C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.685139 · Cited by 32
Regulation of the innate immune cells during pregnancy: An immune checkpoint perspective
Li, W., Xu, X., & Jin, L. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17022 · Cited by 28
Vuletić, A. M., Martinović, K. M., Miletić, N. T., Zoidakis, J., Castellvı́-Bel, S., & Cavic, M. R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.750022 · Cited by 26
DFNA5 regulates immune cells infiltration and exhaustion
Hu, J., Pei, W., Jiang, M., Huang, Y., Dong, F., Jiang, Z., Xu, Y. X., & Li, Z. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02487-0 · Cited by 28
Galectin functions in cancer-associated inflammation and thrombosis
Kruk, L., Braun, A., Cosset, E. C., Gudermann, T. W., & Mammadova‐Bach, E. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1052959 · Cited by 32
Witt, M., Oliveira‐Ferrer, L., Koch‐Nolte, F., Menzel, S., Hell, L., Sturmheit, T., Seubert, E., Weimer, P., Ding, Y., Qi, M., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2346359 · Cited by 29
Nie, J., Wang, C., Zheng, L., Liu, Y., Wang, C., Chang, Y., Hu, Y., Guo, B., Pan, Y., Yang, Q., et al. (2024) · Blood · doi:10.1182/blood.2024024487 · Cited by 28
Skaličková, M., Vanova, K. H., Uher, O., Fialová, J. L., Petrláková, K., Masařík, M., Kejík, Z., Pavel Martasek, E., Pacák, K., & Jakubek, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1479483 · Cited by 28
Obesity, COVID-19 and Immunotherapy: the Complex Relationship!
Finelli, C. (2020) · Immunotherapy · doi:10.2217/imt-2020-0178 · Cited by 27
Inhibition of Melanoma Cell–Intrinsic Tim-3 Stimulates MAPK-Dependent Tumorigenesis
Schatton, T., Itoh, Y., Martins, C. P., Rasbach, E., Singh, P. K., Silva, M., Mucciarone, K., Heppt, M. V., Geddes-Sweeney, J., Stewart, K., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0970 · Cited by 28
Li, H., Yang, D., Hao, M., & Liu, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.972664 · Cited by 27
Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach
Adhikary, S., Pathak, S., Palani, V., Acar, A., Banerjee, A., Al-Dewik, N. I. E., Essa, M. M., Mohammed, S. G. A. A., & Qoronfleh, M. W. (2024) · Biomedicines · doi:10.3390/biomedicines12010217 · Cited by 28
The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer
Yadav, R., Khatkar, R., Yap, K. C.-Y., Kang, C., Lyu, J., SINGH, R. K., Mandal, S., Mohanta, A., Lam, H. Y., Okina, E., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02182-1 · Cited by 29
Struckmeier, A., Gosau, M., & Smeets, R. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.107145 · Cited by 27
Immune dysfunction in Alzheimer disease
Butovsky, O., Rosenzweig, N., Kleemann, K. L., Jorfi, M., Kuchroo, V. K., Tanzi, R. E., & Weiner, H. L. (2025) · Nature reviews. Neuroscience · doi:10.1038/s41583-025-00997-0 · Cited by 41
Self-citationZhai, Y., Celis‐Gutierrez, J., Voisinne, G., Mori, D., Girard, L., Burlet‐Schiltz, O., de Peredo, A. G., Roncagalli, R., & MALISSEN, B. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00575-7 · Cited by 28
Targeting glyco-immune checkpoints for cancer therapy
Manni, M., & Laubli, H. P. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1882989 · Cited by 26
A human receptor occupancy assay to measure anti‐PD ‐1 binding in patients with prior anti‐PD ‐1
Junker, F., Gulati, P., Wessels, U., Seeber, S., Stubenrauch, K., Deak, L. C., Markert, C., Klein, C., Teixeira, P. C., & Kao, H. (2021) · Cytometry Part A · doi:10.1002/cyto.a.24334 · Cited by 26
Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes
Song, Y., Xu, Y., Deng, C., Zhu, X., Fu, J., Chen, H., Lu, J., Xu, H., Song, G., Tang, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.623762 · Cited by 26
Immunotherapy for Triple-Negative Breast Cancer
Cao, Y., Chen, C., Tao, Y., Lin, W., & Wang, P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122003 · Cited by 28
Glycomaterials to Investigate the Functional Role of Aberrant Glycosylation in Glioblastoma
Tondepu, C., & Karumbaiah, L. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101956 · Cited by 27
Gamerith, G., Mildner, F., Merkel, P. A., Harris, K. M., Cooney, L., Lim, N., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222479 · Cited by 26
Chen, H., Zha, J., Tang, R., & Chen, G. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110418 · Cited by 27
Lopresti, L., Tatangelo, V., Baldari, C. T., & Patrussi, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1418527 · Cited by 27
Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential
Lica, J. J., Pradhan, B., Safi, K., Jakóbkiewicz‐Banecka, J., & Hellmann, A. (2024) · Molecules · doi:10.3390/molecules29174280 · Cited by 29
Implantable Biomaterials for Cancer Immunotherapies
Печникова, Н. А., Aggeli, A., Latypova, A., Iaremenko, A. V., Domvri, K., Zubarev, I. V., Chuang, L. I. U., & Yaremenko, A. V. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202416813 · Cited by 26
Differential impact of TIM-3 ligands on NK cell function
Wang, J., Li, H., Kulkarni, A., Anderson, J. L., Upadhyay, P., Onyekachi, O. V., Arantes, L. M. R. B., Banerjee, H., Kane, L., Zhang, X., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010618 · Cited by 26
TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer
Kato, R., Jinnouchi, N., Tuyukubo, T., Ikarashi, D., Matsuura, T., Maekawa, S., Kato, Y., Kanehira, M., Takata, R., Ishida, K., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100918 · Cited by 26
Wang, L., Ge, X., Zhang, Z., Ye, Y.-T., Zhou, Z., Li, M., Yan, H., Wu, L., Bai, Q., Li, J., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.682082 · Cited by 24
Singh, S., Kumar, K., Panda, M., Srivastava, A., Mishra, A., & Prajapati, V. K. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10452-2 · Cited by 27
Jeon, D., Hill, E., Moseman, J. E., & McNeel, D. G. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008799 · Cited by 24
IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer
Pires, I. S., Covarrubias, G., Gomerdinger, V. F., Backlund, C. M., Bueno, E. N., Billingsley, M. M., Pryor, M. L., Shanker, A., Gordon, E., Wu, S., et al. (2025) · Nature Materials · doi:10.1038/s41563-025-02390-9 · Cited by 24
Feng, Z., Qiao, R., Ren, Z., Hou, X., Feng, J., He, X., & Chen, D. (2020) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2020.03.01 · Cited by 23
Sim, J., Park, J., Kim, S., Hwang, S., Sung, K., Lee, J.-E., Yang, S.-H., Cho, K. G., Lee, S. H., Moon, J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042028 · Cited by 24
Malinga, N. Z., Siwele, S. C., Steel, H. C., Kwofie, L. L. I., Meyer, P. W. A., Smit, T., Anderson, R., Rapoport, B. L., & Kgokolo, M. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101384 · Cited by 24
Ji, Q., Wu, Y., Albers, A. E., Fang, M., & Qian, X. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091811 · Cited by 24
Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting
Cerella, C., Dicato, M. A., & Diederich, M. F. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106914 · Cited by 24
Yang, G., Cai, S., Hu, M., Li, C., Yang, L., Zhang, W., Sun, J., Sun, F., Xing, L., & Sun, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04839-4 · Cited by 27
Aye, L., Song, X., Yang, J., Hu, L., Sun, X., Zhou, J., Liu, Q., Yu, H., & Wang, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.695533 · Cited by 23
Intratumoral erythroblastic islands restrain anti-tumor immunity in hepatoblastoma
Wang, Y., Xiang, X., Chen, H., Zhou, L., Chen, S., Zhang, G., Liu, X., Ren, X., Liu, J., Kuang, M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101044 · Cited by 26
Molecular insight into T cell exhaustion in hepatocellular carcinoma
Zhu, Y., Tan, H., Wang, J., Zhuang, H., Zhao, H., & Lu, X. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107161 · Cited by 28
Hu, D., Lyu, X., Li, Z., Ekambaram, P., Dongre, A., Freeman, T. J., Joy, M., Atkinson, J. M., Brown, D. D., Cai, Z., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00969-4 · Cited by 23
Jiao, J., Jiao, D., Yang, F., Zhang, J., Li, Y., Han, D., Zhang, K., Wang, Y., Zhang, R., Yang, A., et al. (2022) · Aging · doi:10.18632/aging.203909 · Cited by 23
Blaeschke, F., Ortner, E., Stenger, D., Mahdawi, J., Apfelbeck, A., Habjan, N., Weißer, T., Kaeuferle, T., Willier, S. M., Kobold, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845499 · Cited by 24
Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects
Banday, A. H., & Abdalla, M. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220819115849 · Cited by 25
Javid, H., Attarian, F., Saadatmand, T., Rezagholinejad, N., Mehri, A., Amiri, H., & Karimi‐Shahri, M. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30402 · Cited by 23
Pan, M., Zhao, H., Jin, R., Leung, P. S. C., & Shuai, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1156212 · Cited by 24
Xu, S., Zhang, N., Rinne, M. L., Sun, H., & Stein, A. M. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12962 · Cited by 23
Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma
Hoeijmakers, L. L., Reijers, I. L. M., & Blank, C. U. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0352 · Cited by 24
Duong, B. Q., Banskota, P., & Falchook, G. S. (2024) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-23-4 · Cited by 23
Du, F., Wang, G., Dai, Q., Huang, J. H., Li, J., Liu, C., Du, K., Tian, H., Deng, Q., Xie, L., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00748-4 · Cited by 25
Engineering strategies of sequential drug delivery systems for combination tumor immunotherapy
Xu, Z., Liu, S., Li, Y., Wu, Y., Tu, J., Chen, Q., & Sun, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.039 · Cited by 26
Gutierrez, M. E., Tang, S., Powderly, J. D., Balmanoukian, A. S., Hoyle, P., Dong, Z., Cheng, L. L., Gong, X., Janik, J. E., Bourayou, N., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf144 · Cited by 22
Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy
Jacquelot, N., Ghaedi, M., Warner, K., Chung, D. C., Crome, S. Q., & Ohashi, P. S. (2021) · Cancers · doi:10.3390/cancers13235967 · Cited by 22
Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias
Panuciak, K., Margas, M., Makowska, K., & Lejman, M. (2022) · Cells · doi:10.3390/cells11010139 · Cited by 22
Beyond PD-L1—Identification of Further Potential Therapeutic Targets in Oral Cancer
Weber, M., Lutz, R., Olmos, M., Glajzer, J., Baran, C., Nobis, C.-P., Möst, T., Eckstein, M., Kesting, M. R., & Ries, J. (2022) · Cancers · doi:10.3390/cancers14071812 · Cited by 22
Mechanism underlying circRNA dysregulation in the TME of digestive system cancer
Wu, Z., Yu, X., Zhang, S., He, Y., & Guo, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.951561 · Cited by 22
Metadata
- Authors
- Wolf, Y., Anderson, A. C., & Kuchroo, V. K.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Kuchroo, Vijay K.
- Venue
- Nature Reviews Immunology
- Published
- 2019-11-01
- Volume
- 20
- Issue
- 3
- Pages
- 173-185
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7327798
- OpenAlex
- W2985205513
- Cited by
- 959
- References
- 159
- Citations by year
- 2026: 98 · 2025: 140 · 2024: 191 · 2023: 160 · 2022: 183 · 2021: 142 · 2020: 44
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R01CA187975)
- National Institute of Allergy and Infectious Diseases (P01AI073748, P01AI056299, P01AI039671)
- National Institute of Neurological Disorders and Stroke (R01NS045937)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- TIM-3, inhibitory receptors, co-inhibitory receptors, immune checkpoint, T cell exhaustion, loss-of-function mutations, antitumor immunity, chronic viral infection, cancer immunotherapy
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Animals, Clinical Trials as Topic, Humans, Signal Transduction, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
